Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Specific studies on the combination of these four peptides together have not yet been conducted
doi: 10.3389/fendo.2020.608428 Received 20 September 2020 Accepted 08 December 2020 Published 26 January 2021 Volume 11 - 2020 Edited by Ilaria Muller, Fondazione IRCCS Ospedale Ca Granda Maggiore Policlinico, Italy Reviewed by Giampaolo Papi, Local Health Unit of Modena, Italy
doi:10.1007/s43032-021-00813-x 269
The project was supported by NIH grants RO1DK 55478 (MWH) and USDA/ARS 6250-5100 (MWH), and the Marilyn Fishman Endocrine Fellows Foundation grant (STC)
and Hansoh Pharmaceutical Group Co
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease)
US$ 24.44
US$ 24.50
US$ 27.59
US$ 26.98
US$ 29.43
US$ 25.98
